TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19207891

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD) 20 mg b.i.d. + surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo + surgery
Number of subjects: 70
Study: 17086096

Group type: EXPERIMENTAL
Intervention: Prednisone (1 mg/kg/day with a maximum dose of 60 mg/day)
Number of subjects: 20
Study: 16488417

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12825489

Group type: EXPERIMENTAL
Intervention: Transfer factor and psychological support
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transfer factor without psychological support
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 20
Study: 10434818

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 0
Study: 7831493

Group type: EXPERIMENTAL
Intervention: PREP system of nursing interventions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Assistance from PREP nurses
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hospital costs for PREP group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard home health control group
Number of subjects: 22
Study: 1977708

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Befunolol
Number of subjects: 15
Study: 530771

Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise at 840 kpm/min with pedalling rates of 40, 60, or 80 rpm.
Number of subjects: 50
Study: 31472039

Group type: EXPERIMENTAL
Intervention: High circulating dipeptidyl peptidase 3 (cDPP3) group (cDPP3 ≥59.1 ng/mL) at inclusion
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Rapid decrease in cDPP3 at 24 hours
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: cDPP3 values measured at inclusion, 24h, 48h, and 72h
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: cDPP3 at inclusion
Number of subjects: 57
Study: 29600897

Group type: EXPERIMENTAL
Intervention: Intravenous esmolol (β1‐adrenergic receptor antagonist)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Volume‐matched saline (placebo)
Number of subjects: 11
Study: 28721700

Group type: EXPERIMENTAL
Intervention: Indapamide SR/amlodipine
Number of subjects: 197

Group type: COMPARATOR
Intervention: Enalapril/amlodipine
Number of subjects: 197
Study: 26613591

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic volume (EDV)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Glucose metabolism and body composition measures
Number of subjects: 65
Study: 24022033

Group type: EXPERIMENTAL
Intervention: Prevention of Care (PoC) approach
Number of subjects: 346

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 346
Study: 21375416

Group type: EXPERIMENTAL
Intervention: Ultrasonically activated shears
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional clip and electrocautery
Number of subjects: 200
Study: 18986282

Group type: EXPERIMENTAL
Intervention: Oral antibacterial drugs
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenously administered antibacterial drugs
Number of subjects: 7
Study: 15691522

Group type: EXPERIMENTAL
Intervention: Bupropion (32% response rate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Venlafaxine (33% response rate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects (n = 20)
Number of subjects: 20
Study: 12924681

Group type: EXPERIMENTAL
Intervention: Engaging Moms Program
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 103
Study: 10390914

Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (ASA) (1.5 mg/kg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard treatment (Sadamin, Partusisten, glucose i.v., amino acids i.v.)
Number of subjects: 31
Study: 8686047

Group type: EXPERIMENTAL
Intervention: Microalbuminuria in rheumatoid arthritis patients
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (sex and age matched)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Duration of disease in patients with microalbuminuria
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: C-reactive protein correlation
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Treatment with gold and penicillamine
Number of subjects: 65
Study: 1828764

Group type: EXPERIMENTAL
Intervention: doxazosin
Number of subjects: 84

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 84
Study: 6286089

Group type: EXPERIMENTAL
Intervention: Radiotherapy to the chest (RC), 3000 rad in two weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No radiotherapy to the chest (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy to the chest (RC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy with periodic reinductions
Number of subjects: 0
Study: 31256660

Group type: EXPERIMENTAL
Intervention: Direct lateral approach
Number of subjects: 150

Group type: COMPARATOR
Intervention: Anterolateral approach
Number of subjects: 150
Study: 28235510

Group type: EXPERIMENTAL
Intervention: Right stellate ganglion block (RSGB) using 10mL of 1% lidocaine.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (placebo).
Number of subjects: 60
Study: 25538263

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 1110

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 1110
Study: 24354454

Group type: EXPERIMENTAL
Intervention: High-fluoride toothpaste (5000 ppm F)
Number of subjects: 130
Study: 22038532

Group type: EXPERIMENTAL
Intervention: Brief psychological intervention (two 1-hour sessions in participants' homes)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care plus researcher contact (Control)
Number of subjects: 58
Study: 19222415

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (100 units)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17612359

Group type: EXPERIMENTAL
Intervention: Cervical high‐velocity low‐amplitude (HVLA) thrust manipulation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (sham‐manual application)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 15
Study: 14725517

Group type: EXPERIMENTAL
Intervention: Acupuncture (n = 109)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo acupuncture (n = 111)
Number of subjects: 220
Study: 11166751

Group type: EXPERIMENTAL
Intervention: 1% chloroprocaine
Number of subjects: 82

Group type: COMPARATOR
Intervention: saline
Number of subjects: 82
Study: 9038494

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 140

Group type: COMPARATOR
Intervention: Open hernia repair
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Preoperative assessment
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Postoperative assessment at 3 months
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Postoperative assessment compared to population norms
Number of subjects: 140
Study: 8294223

Group type: EXPERIMENTAL
Intervention: Naltrexone 25 mg/day for 4 weeks followed by 50 mg/day for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3505536

Group type: EXPERIMENTAL
Intervention: Brand A salbutamol metered-dose inhaler (MDI)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Brand B salbutamol metered-dose inhaler (MDI)
Number of subjects: 31
Study: 29525611

Group type: EXPERIMENTAL
Intervention: Purple potato chips
Number of subjects: 11

Group type: COMPARATOR
Intervention: White potato chips
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Potato phenolic extracts (PPE)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 11
Study: 27741230

Group type: EXPERIMENTAL
Intervention: boceprevir
Number of subjects: 50

Group type: COMPARATOR
Intervention: telaprevir
Number of subjects: 50
Study: 25054392

Group type: EXPERIMENTAL
Intervention: Tapentadol PR (100 - 250 mg bid)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496

Group type: COMPARATOR
Intervention: Morphine CR (40 - 100 mg bid)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Number of subjects: 496

Group type: COMPARATOR
Intervention: Morphine CR
Number of subjects: 496
Study: 22437996

Group type: EXPERIMENTAL
Intervention: Rotating-platform tibial component
Number of subjects: 240

Group type: COMPARATOR
Intervention: All-polyethylene fixed-bearing tibial component
Number of subjects: 240

Group type: COMPARATOR
Intervention: Modular-metal-backed fixed-bearing tibial component
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 240
Study: 21254596

Group type: EXPERIMENTAL
Intervention: Cycloferon with lamivudin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-interferon with cycloferon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 0
Study: 18460985

Group type: EXPERIMENTAL
Intervention: Supervised resistance exercise
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise
Number of subjects: 242

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 242
Study: 16192367

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg qid for 2 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg once a day for 5 days)
Number of subjects: 30
Study: 14646457

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10547110

Group type: EXPERIMENTAL
Intervention: Pyloric ratio measurement (wall thickness/pyloric diameter)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard criteria for diagnosing hypertrophic pyloric stenosis
Number of subjects: 87
Study: 8625171

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 5-FU (1000 mg/m2, days 1-4) with bolus FA (200 mg/m2, days 1-4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bolus 5-FU (375 mg/m2, days 1-5) with bolus FA (200 mg/m2, days 1-5)
Number of subjects: 80
Study: 2404768

Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg q.i.d. orally for 14 days)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 52
Study: 7362504

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2% epinephrine hydrochloride
Number of subjects: 20
Study: 31859528

Group type: EXPERIMENTAL
Intervention: Decrescent intensity training (TR; n=9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (CON; n=8)
Number of subjects: 17
Study: 29260401

Group type: EXPERIMENTAL
Intervention: Post-exercise protein supplementation made from cow's milk (13 g of proteins)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Post-exercise protein supplementation made from rice milk (isocaloric protein-free beverage)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Post-exercise water (control)
Number of subjects: 9
Study: 27565830

Group type: COMPARATOR
Intervention: Home-based vegetable gardening intervention (Harvest for Health) with one-on-one mentorship over 12 months.
Number of subjects: 128
Study: 25116312

Group type: EXPERIMENTAL
Intervention: Multimedia assisted instruction for 3 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no multimedia instruction)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Multimedia assisted instruction
Number of subjects: 96
Study: 22872695

Group type: EXPERIMENTAL
Intervention: LiFE programme (n=107)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Structured programme (n=105)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Sham control programme (n=105)
Number of subjects: 317
Study: 20659368

Group type: EXPERIMENTAL
Intervention: Contraceptive use at three episodes of sexual intercourse
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Withdrawal, putting on a condom before ejaculation, or non-use
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Method use suggestive of greater risk-taking behaviour
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Factors associated with greater pregnancy risk-taking behaviour
Number of subjects: 435
Study: 18361231

Group type: EXPERIMENTAL
Intervention: Tibial rotational alignment determined by medical 1/3 of tibial tubercle (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tibial rotational alignment determined by medial border of tibial tubercle at 0‐9 degrees varus (Group B)
Number of subjects: 60
Study: 16238896

Group type: EXPERIMENTAL
Intervention: IV paracetamol 1 g
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: IV metamizol 1 g
Number of subjects: 38
Study: 12151921

Group type: EXPERIMENTAL
Intervention: Propofol at 600 ng/ml
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propofol at 1000 ng/ml
Number of subjects: 11
Study: 10208787

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 1825

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 1825

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 1825

Group type: EXPERIMENTAL
Intervention: Antiarrhythmics
Number of subjects: 1825

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1825

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 1825

Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 1825

Group type: EXPERIMENTAL
Intervention: Antiplatelets
Number of subjects: 1825
Study: 7838947

Group type: EXPERIMENTAL
Intervention: Community-based programs to increase fruit and vegetable consumption
Number of subjects: 9
Study: 2220582

Group type: EXPERIMENTAL
Intervention: Nuclear pacemakers (VOO)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Nuclear pacemakers (all types)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Lithium-chemistry demand pacemakers (VVI)
Number of subjects: 132
Study: 677431

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.80 mcg/kg body weight/10 min) and Flunitrazepam (1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone (0.05 mg) administered postoperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enflurane (no opiate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pethidine (premedication)
Number of subjects: 0
Study: 7104154

Group type: EXPERIMENTAL
Intervention: pindolol 10 mg three times daily for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: metoprolol 100 mg three times daily for 4 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 18

Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 18
Study: 31049085

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 0.9 mg/Kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous nalbuphine 0.25 mg/Kg
Number of subjects: 100
Study: 28930797

Group type: EXPERIMENTAL
Intervention: Immediate everolimus (EVR-I)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Delayed everolimus (EVR-D)
Number of subjects: 181
Study: 26327289

Group type: EXPERIMENTAL
Intervention: Local treatment focusing on quadriceps strengthening, quadriceps stretching, and taping for fortnight 1, supplemented with individualized global treatment focusing on lower limb posture and movement patterns for fortnight 2, followed by ongoing self-management.
Number of subjects: 37
Study: 27129006

Group type: EXPERIMENTAL
Intervention: Darunavir oral suspension (100 mg/mL, 6 mL) with low-dose ritonavir (100 mg, days 1-5)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Darunavir tablets (600 mg, 2 x 300 mg) with low-dose ritonavir (100 mg, days 1-5)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Darunavir oral suspension (600 mg) with low-dose ritonavir (100 mg, days 1-9)
Number of subjects: 38
Study: 21862196

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC) with hazelnut in 11 subjects
Number of subjects: 904

Group type: COMPARATOR
Intervention: History of hazelnut allergy and/or positive skin tests
Number of subjects: 904

Group type: COMPARATOR
Intervention: Prick-to-prick skin tests with fresh hazelnut
Number of subjects: 904

Group type: COMPARATOR
Intervention: Overall skin test sensitisation to hazelnut
Number of subjects: 904
Study: 20041911

Group type: EXPERIMENTAL
Intervention: Ocinaplon 90 mg t.i.d.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17670917

Group type: EXPERIMENTAL
Intervention: Lifestyle modification (LSM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle modification and metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 15732092

Group type: EXPERIMENTAL
Intervention: BILN‐2061, 500 mg twice-daily for 2 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11874817

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg every 6 h, n = 71)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg every 12 h, n = 62)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo (n = 66)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Comparison of budesonide and prednisolone
Number of subjects: 199
Study: 10232362

Group type: EXPERIMENTAL
Intervention: c-mpl ligands (recombinant thrombopoietin or pegylated megakaryocyte growth and development factor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: c-mpl ligands
Number of subjects: 0
Study: 8522634

Group type: EXPERIMENTAL
Intervention: Nisoldipine 20 mg once daily
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Nisoldipine 60 mg once daily
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Nisoldipine (20 mg and 60 mg)
Number of subjects: 483
Study: 2347498

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Social activity control group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 48
Study: 383011

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 27

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 27
Study: 31444972

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy ± bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noninvasive biomarkers
Number of subjects: 0
Study: 28958110

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU every 2 weeks for 12 weeks)
Number of subjects: 60
Study: 26682790

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe sleep-disordered breathing (SDB) determined by a 2-channel screening device (ApneaLink)
Number of subjects: 6876

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe SDB in women
Number of subjects: 6876

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe SDB in men
Number of subjects: 6876

Group type: EXPERIMENTAL
Intervention: Age groups and prevalence of SDB
Number of subjects: 6876

Group type: EXPERIMENTAL
Intervention: Body mass index (per 5 units)
Number of subjects: 6876

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (per 5% decrement from 45%)
Number of subjects: 6876

Group type: EXPERIMENTAL
Intervention: Age (per 10-year difference to 60 years)
Number of subjects: 6876

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 6876

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 6876
Study: 25634768

Group type: EXPERIMENTAL
Intervention: Early specific intervention program carried out by rheumatologists
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard care (Control Group)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Early specific intervention program
Number of subjects: 123
Study: 23775099

Group type: EXPERIMENTAL
Intervention: Polidocanol foam (3%)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Liquid sclerotherapy (polidocanol 3%)
Number of subjects: 130
Study: 20568428

Group type: EXPERIMENTAL
Intervention: Three-step acupuncture combined with oral administration of Aspirin for six months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral administration of Aspirin alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Three-step acupuncture combined with oral administration of Aspirin
Number of subjects: 120
Study: 18843003

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16642971

Group type: EXPERIMENTAL
Intervention: Perforated Makrolon curtains placed in front of racks, with air ventilation through the corridor and holes in the curtain.
Number of subjects: 0
Study: 14664898

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day (n=16)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day (n=16)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (n=16)
Number of subjects: 150
Study: 10623698

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 473

Group type: COMPARATOR
Intervention: Three cycles of CMF
Number of subjects: 473

Group type: COMPARATOR
Intervention: Six cycles of CMF
Number of subjects: 473
Study: 9124805

Group type: EXPERIMENTAL
Intervention: Temporal lobectomy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Continued medical management
Number of subjects: 81
Study: 8455298

Group type: EXPERIMENTAL
Intervention: Soil and interior dust abatement and loose paint removal (study group)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Interior dust abatement and loose paint removal (comparison group A)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Only interior loose paint removal (comparison group B)
Number of subjects: 152
Study: 3463726

Group type: EXPERIMENTAL
Intervention: Three different dentifrices
Number of subjects: 83
Study: 29917215

Group type: EXPERIMENTAL
Intervention: Micronised dispersible ferric pyrophosphate plus alpha-lactalbumin (MDFP-AL), 30 mg of MDFP-AL per day for 30 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ferrous gluconate (FG), 80 mg of FG per day for 30 days
Number of subjects: 50